Summary by Futu AI
On December 31, 2023, a Schedule 13G was filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a collective beneficial ownership of 9.8% of Zyversa Therapeutics, Inc.'s common stock. This group, consisting of investment advisors and directors from Texas and Ontario, Canada, has shared voting and dispositive power over 160,671 shares of the biopharmaceutical company. The filing, which was completed on February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Zyversa Therapeutics. The Schedule 13G is a regulatory document required by the SEC when parties exceed certain thresholds of ownership in a company's stock.